Media Coverage of PrEP

May 2017

April 2017

  • Providers Who Prescribe PrEP Don't See Most Patients Increasing Risky Sexual Behavior - A new study examining medical provider attitudes toward prescribing PrEP to prevent HIV found that those who already prescribe it do not see widespread increases in risky sexual behavior among their patients as a result.
  • PrEP is Approved in Scotland - The Scottish Medicines Consortium announced that it had accepted tenofovir disoproxil/emtricitabine (TDF/FTC – Truvada) for use within the Scottish National Health Service as pre-exposure prophylaxis (PrEP) to prevent HIV infection.
  • PrEP Should be Given to All Breastfed Babies, Researchers Say - An international group of researchers involved in the ANRS 12174 randomised controlled trial of pre-exposure prophylaxis (PrEP) for infants say that it is high time we started giving PrEP to all breastfed babies of HIV-positive mothers in countries where the likelihood of transmission via breastfeeding remains significant.

March 2017

  • Tshwane Men to Get the HIV Prevention Pill - Men who have sex with men will soon be able to get the HIV prevention pill in Tshwane. As of April 1, men who have sex with men will be able to get PrEP from a Hatfield clinic in central Pretoria. The clinic is run by health advocacy organization OUT LGBT Well-being, which already provides HIV prevention services, such as a needle exchange program, to people at high risk of HIV.

February 2017

December 2016

October 2016

September 2016

  • New York Clinic Outlines How to Improve Uptake of PrEP by Transgender People - Rolling out PrEP right. aidsmap reporter Roger Pebody recently published a careful look at how one New York City clinic brought PrEP to a transgender community. Pebody’s story documents the steps taken by the Callen-Lourde Community Health Center to navigate the fault lines of a marginalized people and deliver a potent tool for HIV prevention.
  • Nationwide PrEP Search Engine Debuts at US Conference on AIDS - Emory University and partners have developed a new web-based directory of PrEP providers across the US. The search engine can be used to help people find physicians or clinics in their area that will prescribe TDF/FTC as oral PrEP.

August 2016

  • PrEP Introduction for Adolescent Girls and Young Women - In a commentary in Lancet HIV, authors Mathur, Pilgrim and Pulerwitz from the Population Council propose a framework that outlines the range of factors and actors to consider when designing PrEP introduction strategies for adolescent girls and young women.
  • HIV Prevention Drug Truvada Won't Be Subsidised in Australia - A major Australian newspaper reports that the nation's drug funding panel has ruled PrEP will not be funded by taxpayers in Australia this year, The department of health announced that the price set by the drug's sponsor, Gilead Sciences, was too high.
  • NHS Can Fund 'Game-changing' PrEP HIV Drug, Court Says - AIDS campaigners are celebrating a victory after a court ruled that NHS England can pay for “game-changer” drugs that prevent people being infected with HIV by their partners.

July 2016

June 2016

May 2016

April 2016

  • University of California Launches First in the Nation PrEP Demo Project in Transgender People - The California HIV/AIDS Research Program (CHRP) of the University of California announced that it has awarded grants to provide and evaluate PrEP among transgender people at risk for HIV acquisition in California. This is the first PrEP demonstration project in the US to focus exclusively on transgender people.
  • NHS To Reconsider Its Decision Not To Provide The HIV Prevention Drug - The NHS in England is to reconsider its controversial decision not to provide Truvada for HIV prevention.
  • PrEP Pricing Problems - James Krellenstein and Jeremiah Johnson write in the April issue of TAGline about the high cost of PrEP as a deterrent to increased uptake. They discuss problems with Gilead’s medical and co-pay assistance program (MAP/CAP), the company’s reluctance to prioritize PrEP and how Gilead is “profiting from its PrEP monopoly”. The article ends with recommendations for Gilead which include increasing CAP contribution and aggressively promoting CAP and MAP.
  • Gilead Statement on the Approval of PrEP in Peru - The Peru Ministry of Health has approved the use of fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for PrEP.

March 2016

February 2016

January 2016

  • Dramatic Increase in Preexposure Prophylaxis Use Among MSM in Washington State - Using data from an annual survey conducted at the Seattle Pride Parade (2009-2015), authors of an article published in AIDS found that PrEP awareness and use among MSM in Seattle, Washington was high in 2015. In 2012 to 2015, among high-risk MSM, PrEP awareness increased from 13 percent to 86 percent and PrEP use increased from 5 percent to 31 percent.
  • Approval of Truvada a Game Changer in Anti-HIV/AIDS Effort - Wanjiru Mukoma of LVCT Health applauds the recent approval of Truvada by Kenya and stresses that developing guidelines, fighting stigma and collaborating with stakeholders is key to an efficient integration of PrEP in health services.

December 2015

  • When Can We Expect PrEP 2.0? - Benjamin Ryan of POZ discusses what's in the PrEP pipeline, looking forward to long-acting injectables and drugs less toxic than Truvada.
  • Why Don't Women Know About This Lifesaving Drug? - 1 in 4 people living with HIV in the United States are women. Naveen Kumar of Refinery29 discusses why more women aren’t talking about PrEP—despite the fact that it's been FDA-approved since 2012—and the potential PrEP has to improve women’s health.

November 2015

October 2015

September 2015

  • Millions More Need HIV Treatment, WHO Says - The World Health Organization issued sweeping new guidelines on Wednesday that could put millions more people on HIV drugs than are now getting them. The recommendations could go a long way toward halting the epidemic, health officials say, but would cost untold billions of dollars not yet committed.
  • ITM Launches Study on a Preventative Drug for HIV - The Institute for Tropical Medicine (ITM) in Antwerp has launched the Be-PrEP-ared study, the first Flemish research project on the applicability of preventative HIV medication. The researchers hope that the study, which focuses on gay men, can help to reduce the high number of new HIV infections among the target group.

August 2015

July 2015

June 2015

May 2015

April 2015

March 2015

February 2015

News Spotlight